IGF2BP2-dependent activation of ERBB2 signaling contributes to acquired resistance to tyrosine kinase inhibitor in differentiation therapy of radioiodine-refractory papillary thyroid cancer.
Cancer Lett
; 527: 10-23, 2022 02 28.
Article
in En
| MEDLINE
| ID: mdl-34896211
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thyroid Neoplasms
/
Receptor, ErbB-2
/
Protein Kinase Inhibitors
/
Thyroid Cancer, Papillary
Limits:
Humans
Language:
En
Journal:
Cancer Lett
Year:
2022
Type:
Article